Type 2 Diabetes Academy: Advancing Kidney Health in Diabetes

This program is supported by an independent educational grant from Novo Nordisk. This education program is only available to healthcare professionals in the USA. Please read the full disclosures and Continuing Education Information here before joining: https://app.medalleducation.com/event... Join diabetes and kidney disease experts Dr. Leigh Perreault, Dr. Robert Busch, and Dr. Sankar Navaneethan for this accredited, interactive teaching session focused on the latest updates and evidence in early detection and management of chronic kidney disease in patients with type 2 diabetes for 2026. Through real-world cases and expert-led discussion and live Q&A, faculty will translate emerging evidence and guidelines into practical strategies for CKD screening, GLP-1 RA integration, and multidisciplinary care. Accreditation: 1.5 AMA PRA Category 1 Credit™ Session Highlights Optimizing CKD Detection and Multidisciplinary Care in Type 2 Diabetes This case-based session explores how earlier identification of CKD, appropriate use of GLP-1 receptor agonists, and coordinated team-based care can improve outcomes for patients with T2D and CKD: Review key 2025–2026 evidence and guideline updates influencing CKD screening expectations in people with type 2 diabetes, including contemporary use of eGFR and uACR in routine care Examine how kidney risk stratification is evolving to inform monitoring intensity, therapeutic timing, and cross-specialty referral in current practice Discuss recent and emerging data on GLP-1 receptor agonists in patients with T2D and CKD, with a focus on renal outcomes, cardiovascular risk modification, and patient selection Engage in expert-level case discussion, live Q&A and interactive polling highlighting real-world controversies, decision points, and practice variation entering 2026 With advocacy from Diabetes Sisters. Learning objectives 1. Implement evidence-based CKD screening protocols for patients with T2D to ensure early detection and intervention: Integrate annual eGFR and uACR testing into routine diabetes care, addressing common barriers to implementation. Utilize test results to stratify CKD risk and determine appropriate monitoring frequency and therapeutic interventions. Optimize workflow strategies to increase uACR ordering rates, overcoming structural and system-level barriers in outpatient and primary care settings. 2. Incorporate GLP-1 RAs into treatment plans for T2D and CKD based on current guideline recommendations: Identify appropriate patient populations for GLP-1 RA initiation, considering renal and cardiovascular benefits alongside glycemic control. Select the most suitable GLP-1 RA formulation based on patient-specific factors, including CKD stage, cardiovascular risk, and tolerability. Integrate GLP-1 RAs into multimodal treatment regimens, ensuring appropriate sequencing and combination with other CKD-protective therapies. 3. Apply a deep understanding of the pathophysiological overlap between T2D and CKD to implement a multidisciplinary, team-based approach that improves patient outcomes: Leverage knowledge of shared pathophysiological pathways of T2D and CKD to guide earlier detection and targeted interventions. Establish collaborative workflows between endocrinologists, nephrologists, and primary care providers to enhance care coordination. Engage patients in shared decision-making, incorporating patient preferences and treatment adherence considerations. Utilize clinical decision-support tools and team-based care models to streamline chronic disease management and improve long-term outcomes.